Oyster Point Pharma (OYST) Financials

$11.17

$0.00 (0.00%)

As on 12-Jan-2023 09:30EDT

Market cap

$300 Mln

Revenue (TTM)

$20 Mln

P/E Ratio

--

P/B Ratio

2.4

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Operating Revenue	19.58	24.54	--	--	--	--
Cost of Revenue	4.52	1.53	--	--	--	--
Gross Profit	15.07	23.01	--	--	--	--
Operating Expenses	173.52	119.67	70.99	47.30	16.74	5.68
Operating Profit (EBIT)	-158.45	-96.66	-70.99	-47.30	-16.74	-5.68
Other Income	-5.87	-0.27	0.47	--	--	--
Profit before Tax	-176.65	-100.66	-70.52	-45.71	-16.50	-6.60
Provision for Tax	--	--	--	--	--	--
Profit after Tax (Net Income)	-176.65	-100.66	-70.52	-45.71	-16.50	-6.60
Minority Interest	--	--	--	--	--	--
Consolidated Profit	-176.65	-100.66	-70.52	-45.71	-16.50	-19.14

Liabilities ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Shareholder's Funds	-22.20	99.54	186.66	137.30	-38.24	-21.89
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	102.21	94.28	0.27	0.51	43.01	43.00
Current Liabilities	29.20	28.80	10.98	5.40	0.94	2.07
Total Liabilities	138.70	222.62	197.91	143.21	5.70	23.17

Assets ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Non-Current Assets	11.49	7.37	1.54	1.03	0.09	--
Current Assets	97.71	215.25	196.37	142.18	5.62	23.17
Total Assets	138.40	222.62	197.91	143.21	5.70	23.17
Total Debt*	94.72	92.73	0.69	0.81	0.06	--
Net Current Assets	68.51	186.45	185.39	136.78	4.68	21.11

Cashflow ($ Mln)	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Cash From Operating Activities	--	-89.37	-58.40	-40.82	-17.08	-4.67
Cash Flow from Investing Activities	--	-1.49	-0.70	-0.20	-0.20	-0.20
Cash from Financing Activities	--	91.64	112.55	174.99	174.99	26.18
Net Cash Inflow / Outflow	--	0.79	53.45	--	--	--

Financials Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Adjusted EPS ($)	-6.64	-3.84	-2.73	-3.27	-1.20	--
Cash EPS ($)	--	-3.84	-2.71	-3.27	-1.20	--
Adjusted Book Value ($)	--	3.80	7.22	9.81	--	--
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-3.41	-2.26	-2.92	-1.24	--
Free Cash Flow per Share ($)	--	-3.47	-2.28	-2.93	-1.24	--

Profitability Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
ROCE (%)	--	-53.03	-43.34	-91.49	54.94	--
ROE (%)	--	-70.34	-43.54	-92.29	54.88	--
ROA (%)	-101.35	-47.87	-41.35	-61.39	-114.29	--
EBIT Margin (%)	-839.04	-394.98	--	--	--	--
Net Margin (%)	-1,287.59	-414.76	-15,036.25	--	--	--
Cash Profit Margin (%)	0.00	--	--	--	--	--

Growth Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Revenue Growth (%)	9.15	--	--	--	--	--
EBIT Growth (%)	-106.16	-37.44	-54.27	-176.99	-150.01	--
Net Profit Growth (%)	-118.55	-42.74	-54.27	-176.99	-150.01	--
EPS Growth (%)	-113.24	-0.41	0.17	-1.73	--	--
Book Value Growth (%)	-115.67	--	--	--	--	--

Valuation Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Price / Earnings	--	-4.75	-6.90	-7.48	--	--
Price / Book Value	2.39	4.80	2.61	2.49	--	--
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-1.99	-3.90	-4.21	-4.46	--	--
Close Price ($)	5.62	18.26	18.82	24.44	--	--
High Price ($)	19.98	25.89	41.37	27.73	--	--
Low Price ($)	3.46	9.86	17.24	13.26	--	--
Market Cap ($ Cr)	299.85	--	--	--	--	--

Solvency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debt to Equity	-4.15	0.93	0.00	0.01	0.00	--
Short term debt to equity ratio	-0.03	0.01	--	--	--	--
Current Ratio	3.35	7.47	17.88	26.33	5.98	11.21
Quick Ratio	3.11	7.26	--	--	--	--
Interest Coverage	-13.33	-25.96	--	--	--	-13.53

Operating Efficiency Ratios	TTM	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16	Dec-15	Dec-14	Dec-13	Dec-12
Debtors to sales (%)	67.32	27.12	--	--	--	--
Asset Turnover	0.11	0.12	--	--	--	--
Receivable days	--	99.07	--	--	--	--
Inventory Days	--	1,457.65	--	--	--	--
Payable days	--	1,050.84	--	--	--	--
Cash Conversion Cycle	--	505.88	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.